胰腺炎住院期间痛风发作的风险因素:一项回顾性单中心研究

注册号:

Registration number:

ChiCTR2600125428 

最近更新日期:

Date of Last Refreshed on:

2026-05-27 08:45:41 

注册时间:

Date of Registration:

2026-05-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

胰腺炎住院期间痛风发作的风险因素:一项回顾性单中心研究

Public title:

Risk Factors for In-Hospital Gout Flares in Pancreatitis:A Retrospective Single-Center Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

急性胰腺炎患者住院期间痛风发作的危险因素分析

Scientific title:

Risk Factors for In-Hospital Gout Flares in Pancreatitis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周颖 

研究负责人:

周颖 

Applicant:

Ying Zhou 

Study leader:

Ying,Zhou 

申请注册联系人电话:

Applicant telephone:

+86 574 87018587

研究负责人电话:

Study leader's
telephone:

+86 574 8701 8587

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

drzhouying07@126.com

研究负责人电子邮件:

Study leader's E-mail:

drzhouying07@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省宁波市鄞州区兴宁路57号

研究负责人通讯地址:

浙江省宁波市鄞州区兴宁路57号

Applicant address:

No. 57 Xingning Road, Yinzhou District, Ningbo, Zhejiang Province, China

Study leader's address:

No. 57 Xingning Road, Yinzhou District, Ningbo, Zhejiang Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

宁波市医疗中心李惠利医院

Applicant's institution:

Ningbo Medical Center Li Huili Hospital

研究负责人所在单位:

宁波市医疗中心李惠利医院

Affiliation of the Leader:

Ningbo Medical Center Li Huili Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

李惠利医院伦审2026 研第166号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宁波市医疗中心李惠利医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Ningbo Medical Center Li Huili Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-24 00:00:00

伦理委员会联系人:

章培

Contact Name of the ethic committee:

Zhang Pei

伦理委员会联系地址:

浙江省宁波市鄞州区兴宁路57号

Contact Address of the ethic committee:

No. 57 Xingning Road, Yinzhou District, Ningbo, Zhejiang Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 574 87018834

伦理委员会联系人邮箱:

Contact email of the ethic committee:

542805676@qq.com

研究实施负责(组长)单位:

宁波市医疗中心李惠利医院

Primary sponsor:

Ningbo Medical Centre Lihuili Hospital

研究实施负责(组长)单位地址:

浙江省宁波市鄞州区兴宁路57号

Primary sponsor's address:

No. 57 Xingning Road, Yinzhou District, Ningbo, Zhejiang Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波市医疗中心李惠利医院

具体地址:

浙江省宁波市鄞州区兴宁路57号

Institution
hospital:

Ningbo Medical Centre Lihuili Hospital

Address:

No. 57 Xingning Road, Yinzhou District, Ningbo, Zhejiang Province, China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

No funding was received for this study.

研究疾病:

急性胰腺炎  

Target disease:

Acute pancreatitis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1.主要目的:急性胰腺炎患者住院期间出现痛风发作的危险因素。 2.次要目的:痛风发作对急性胰腺炎住院日、住院费用的影响。  

Objectives of Study:

Primary objective: To explore potential risk factors for gout flares during hospitalization in patients with acute pancreatitis. Secondary objective: To assess the effect of gout flares on length of hospital stay and hospital costs.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.入院时已经存在痛风发作;
2.其他病因导致的关节肿痛;
3.病例资料不齐全;

Exclusion criteria:

1.At admission, the patient already had a gout flare.
2.Other causes of joint pain and swelling could not be excluded.
3.Relevant clinical data were incomplete.

研究实施时间:

Study execute time:

From 2026-05-01 00:00:00 To 2027-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-05 00:00:00 To 2026-06-30 00:00:00

干预措施:

Interventions:

组别:

发作组

样本量:

40

Group:

Gout flare group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

未发作组

样本量:

49

Group:

Non-gout flare group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

宁波市医疗中心李惠利医院 

单位级别:

三级甲等 

Institution
hospital:

Ningbo Medical Centre Lihuili Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

既往预防痛风复发药物使用情况

指标类型:

次要指标

Outcome:

Use of medications for gout flare prophylaxis prior to admission

Type:

Secondary indicator

测量时间点:

测量方法:

依据电子病历及既往健康档案记录既往用药史

Measure time point of outcome:

Measure method:

Use of medications for gout flare prophylaxis prior to admission was obtained from electronic medical records and prior medication records

指标中文名:

胰腺炎严重程度

指标类型:

次要指标

Outcome:

Classification of severity of acute pancreatitis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

NSAIDs药物治疗痛风使用情况

指标类型:

次要指标

Outcome:

use of NSAIDs for gout treatment

Type:

Secondary indicator

测量时间点:

测量方法:

依据住院期间用药医嘱记录确定

Measure time point of outcome:

Measure method:

NSAID use history was obtained from medication orders in electronic medical records

指标中文名:

秋水仙碱治疗痛风使用情况

指标类型:

次要指标

Outcome:

Use of colchicine for gout treatment

Type:

Secondary indicator

测量时间点:

测量方法:

依据住院期间用药医嘱记录确定

Measure time point of outcome:

Measure method:

Use of colchicine for gout treatment was obtained from medication orders in electronic medical records

指标中文名:

利尿剂使用情况

指标类型:

次要指标

Outcome:

Use of diuretic medications

Type:

Secondary indicator

测量时间点:

测量方法:

通过电子病历用药医嘱系统记录获取

Measure time point of outcome:

Measure method:

Diuretic use was identified from medication order records

指标中文名:

入院24小时内液体复苏量

指标类型:

次要指标

Outcome:

Fluid resuscitation volume within the first 24 hours of admission

Type:

Secondary indicator

测量时间点:

测量方法:

通过电子病历输液医嘱及执行记录统计获得

Measure time point of outcome:

Measure method:

Fluid resuscitation volume within the first 24 hours was calculated from medication orders and infusion records

指标中文名:

饮酒史

指标类型:

次要指标

Outcome:

Alcohol consumption history

Type:

Secondary indicator

测量时间点:

测量方法:

电子病历记录

Measure time point of outcome:

Measure method:

Alcohol consumption history was obtained from electronic medical records

指标中文名:

血尿素氮

指标类型:

次要指标

Outcome:

Blood urea nitrogen

Type:

Secondary indicator

测量时间点:

测量方法:

采用医院检验科自动生化分析仪检测

Measure time point of outcome:

Measure method:

Blood urea nitrogen was measured using an automated biochemical analyzer

指标中文名:

是否首次胰腺炎发作

指标类型:

次要指标

Outcome:

First episode of acute pancreatitis(Yes/No)

Type:

Secondary indicator

测量时间点:

测量方法:

通过电子病历既往住院记录及病史判断是否为首次发作

Measure time point of outcome:

Measure method:

First episode of acute pancreatitis was determined based on prior hospitalization records and medical history

指标中文名:

既往糖尿病病史

指标类型:

次要指标

Outcome:

history of diabetes mellitus

Type:

Secondary indicator

测量时间点:

测量方法:

据电子病历既往诊断及病程记录确定

Measure time point of outcome:

Measure method:

Diabetes mellitus was identified from electronic medical records

指标中文名:

既往高脂血症病史

指标类型:

次要指标

Outcome:

history of hyperlipidemia

Type:

Secondary indicator

测量时间点:

测量方法:

据电子病历既往诊断及病程记录确定

Measure time point of outcome:

Measure method:

Hyperlipidemia was identified based on documented clinical diagnosis and laboratory data

指标中文名:

抗生素使用情况

指标类型:

次要指标

Outcome:

Use of antibiotic

Type:

Secondary indicator

测量时间点:

测量方法:

依据住院期间用药医嘱记录确定

Measure time point of outcome:

Measure method:

Antibiotic use was obtained from medication orders in electronic medical records

指标中文名:

甘油三酯

指标类型:

次要指标

Outcome:

Triglycerides

Type:

Secondary indicator

测量时间点:

测量方法:

采用医院检验科自动生化分析仪检测

Measure time point of outcome:

Measure method:

Triglycerides were measured using an automated biochemical analyzer

指标中文名:

肌酐

指标类型:

次要指标

Outcome:

Serum creatinine

Type:

Secondary indicator

测量时间点:

测量方法:

采用医院检验科自动生化分析仪检测

Measure time point of outcome:

Measure method:

Serum creatinine was measured using an automated biochemical analyzer

指标中文名:

既往肾功能不全病史

指标类型:

次要指标

Outcome:

history of renal insufficiency

Type:

Secondary indicator

测量时间点:

测量方法:

据电子病历既往诊断及病程记录确定

Measure time point of outcome:

Measure method:

Renal insufficiency was identified based on clinical diagnosis and laboratory evidence

指标中文名:

年龄

指标类型:

次要指标

Outcome:

Age

Type:

Secondary indicator

测量时间点:

测量方法:

电子病历系统记录出生日期计算

Measure time point of outcome:

Measure method:

Age was calculated from date of birth in electronic medical records.

指标中文名:

既往12个月尿酸值

指标类型:

次要指标

Outcome:

Serum uric acid levels within the past 12 months

Type:

Secondary indicator

测量时间点:

测量方法:

通过电子病历检验系统调取过去12个月内最近检测结果

Measure time point of outcome:

Measure method:

Serum uric acid levels within the past 12 months were retrieved from laboratory records in electronic medical records

指标中文名:

既往降尿酸药物使用情况

指标类型:

次要指标

Outcome:

use of urate-lowering therapy for gout flare prevention prior to admission

Type:

Secondary indicator

测量时间点:

测量方法:

依据电子病历及既往健康档案记录既往用药史

Measure time point of outcome:

Measure method:

Use of urate-lowering therapy for gout flare prevention prior to admission was obtained from electronic medical records and prior health records

指标中文名:

住院费用

指标类型:

次要指标

Outcome:

Hospitalization cost

Type:

Secondary indicator

测量时间点:

测量方法:

从电子病历及医院信息系统中获取。

Measure time point of outcome:

Measure method:

Hospitalization cost was obtained from electronic medical records and the hospital information system.

指标中文名:

肠内外营养支持使用情况

指标类型:

次要指标

Outcome:

use of enteral or parenteral nutrition support

Type:

Secondary indicator

测量时间点:

测量方法:

依据营养支持治疗医嘱记录确定

Measure time point of outcome:

Measure method:

Use of enteral or parenteral nutrition support was recorded from medical orders

指标中文名:

身高

指标类型:

次要指标

Outcome:

Height

Type:

Secondary indicator

测量时间点:

测量方法:

体格检查/电子病历记录

Measure time point of outcome:

Measure method:

Height was recorded from electronic medical records or physical examination.

指标中文名:

CRRT情况

指标类型:

次要指标

Outcome:

use of CRRT

Type:

Secondary indicator

测量时间点:

测量方法:

通过重症监护记录及治疗医嘱系统获取

Measure time point of outcome:

Measure method:

CRRT use was obtained from ICU treatment records

指标中文名:

性别

指标类型:

次要指标

Outcome:

Sex

Type:

Secondary indicator

测量时间点:

测量方法:

从电子病历及医院信息系统中获取。

Measure time point of outcome:

Measure method:

Sex was obtained from electronic medical records and the hospital information system.

指标中文名:

既往冠心病病史

指标类型:

次要指标

Outcome:

history of coronary heart disease

Type:

Secondary indicator

测量时间点:

测量方法:

据电子病历既往诊断及病程记录确定

Measure time point of outcome:

Measure method:

Coronary heart disease was identified from documented medical records

指标中文名:

胰腺炎病因分型

指标类型:

次要指标

Outcome:

Etiology of acute pancreatitis

Type:

Secondary indicator

测量时间点:

测量方法:

结合病史、实验室及影像学检查综合判断

Measure time point of outcome:

Measure method:

Etiology of acute pancreatitis was determined based on clinical, laboratory, and imaging data

指标中文名:

空腹血糖

指标类型:

次要指标

Outcome:

Fasting blood glucose

Type:

Secondary indicator

测量时间点:

测量方法:

采用医院检验科自动生化分析仪检测

Measure time point of outcome:

Measure method:

Fasting blood glucose was measured using an automated biochemical analyzer

指标中文名:

高密度脂蛋白胆固醇

指标类型:

次要指标

Outcome:

High-density lipoprotein cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

采用医院检验科自动生化分析仪检测

Measure time point of outcome:

Measure method:

High-density lipoprotein cholesterol was measured using an automated biochemical analyzer

指标中文名:

住院天数

指标类型:

次要指标

Outcome:

Length of hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

从电子病历及医院信息系统中获取。

Measure time point of outcome:

Measure method:

Length of hospital stay was defined as days from admission to discharge, according to electronic medical records and the hospital information system.

指标中文名:

低密度脂蛋白胆固醇

指标类型:

次要指标

Outcome:

Low-density lipoprotein cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

采用医院检验科自动生化分析仪检测

Measure time point of outcome:

Measure method:

Low-density lipoprotein cholesterol was measured using an automated biochemical analyzer

指标中文名:

呼吸功能衰竭

指标类型:

次要指标

Outcome:

Respiratory failure

Type:

Secondary indicator

测量时间点:

测量方法:

依据氧合指数及呼吸支持情况判定

Measure time point of outcome:

Measure method:

Respiratory failure was defined based on oxygenation indices and need for respiratory support

指标中文名:

激素治疗痛风使用情况

指标类型:

次要指标

Outcome:

Corticosteroid use for gout treatment

Type:

Secondary indicator

测量时间点:

测量方法:

依据电子病历及既往健康档案记录既往用药史

Measure time point of outcome:

Measure method:

Corticosteroid use history was obtained from electronic medical records

指标中文名:

既往高血压病史

指标类型:

次要指标

Outcome:

history of hypertension

Type:

Secondary indicator

测量时间点:

测量方法:

根据电子病历中既往诊断记录及用药史确定

Measure time point of outcome:

Measure method:

Hypertension was identified based on documented diagnoses and medical history in electronic medical records

指标中文名:

吸烟史

指标类型:

次要指标

Outcome:

Smoking history

Type:

Secondary indicator

测量时间点:

测量方法:

电子病历记录

Measure time point of outcome:

Measure method:

Smoking history was obtained from electronic medical records

指标中文名:

尿酸

指标类型:

主要指标

Outcome:

Serum uric acid levels

Type:

Primary indicator

测量时间点:

测量方法:

通过电子病历系统获取医院检验科生化检测的血清尿酸结果。

Measure time point of outcome:

Measure method:

Serum uric acid levels were obtained from the hospital electronic medical record system, and measured in the central laboratory using an automated biochemical analyzer.

指标中文名:

既往痛风史

指标类型:

次要指标

Outcome:

History of gout

Type:

Secondary indicator

测量时间点:

测量方法:

据电子病历既往诊断及病程记录确定

Measure time point of outcome:

Measure method:

History of gout was obtained from electronic medical records

指标中文名:

是否合并器官衰竭

指标类型:

次要指标

Outcome:

Organ failure

Type:

Secondary indicator

测量时间点:

测量方法:

依据临床评分系统及器官功能监测结果判定

Measure time point of outcome:

Measure method:

Organ failure was defined based on clinical scoring systems and organ function monitoring

指标中文名:

超敏C反应蛋白

指标类型:

次要指标

Outcome:

C-reactive protein

Type:

Secondary indicator

测量时间点:

测量方法:

采用医院检验科自动生化分析仪检测

Measure time point of outcome:

Measure method:

C-reactive protein was measured using immunoturbidimetric assay on an automated analyzer

指标中文名:

体重

指标类型:

次要指标

Outcome:

weight

Type:

Secondary indicator

测量时间点:

测量方法:

体格检查/电子病历记录

Measure time point of outcome:

Measure method:

Body weight was recorded from electronic medical records or physical examination

指标中文名:

尿酸波动值

指标类型:

主要指标

Outcome:

Amount of uric acid change

Type:

Primary indicator

测量时间点:

测量方法:

根据电子病历检验报告单,入院时尿酸值-痛风发作前/出院前尿酸值。

Measure time point of outcome:

Measure method:

Change in serum uric acid level (Δ uric acid), calculated from electronic medical records and laboratory reports, defined as admission serum uric acid minus pre-flare/discharge serum uric acid.

指标中文名:

肾功能衰竭

指标类型:

次要指标

Outcome:

Renal failure

Type:

Secondary indicator

测量时间点:

测量方法:

依据血肌酐水平及尿量变化标准判断

Measure time point of outcome:

Measure method:

Renal failure was defined according to serum creatinine levels and urine output criteria

指标中文名:

总胆固醇

指标类型:

次要指标

Outcome:

Total cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

采用医院检验科自动生化分析仪检测

Measure time point of outcome:

Measure method:

Total cholesterol was measured using an automated biochemical analyzer

指标中文名:

BMI

指标类型:

次要指标

Outcome:

BMI

Type:

Secondary indicator

测量时间点:

测量方法:

根据身高体重计算

Measure time point of outcome:

Measure method:

BMI was calculated as weight (kg)/height (m2)

指标中文名:

血浆置换情况

指标类型:

次要指标

Outcome:

use of plasmapheresis

Type:

Secondary indicator

测量时间点:

测量方法:

通过重症监护记录及治疗医嘱系统获取

Measure time point of outcome:

Measure method:

use of plasmapheresis was obtained from ICU treatment records

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后半年内,通过备案系统网址共享数据https://www.medicalresearch.org.cn/。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within six months of publication, share data via the filing system website https://www.medicalresearch.org.cn/.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

一、病例资料收集 本研究采用回顾性研究设计,通过医院电子病历系统及既往健康档案收集相关临床资料。 1. 一般临床资料 包括性别、年龄、身高、体重、体质量指数(BMI)、吸烟史及饮酒史。 2. 基础疾病及既往病史 包括高血压、冠心病、糖尿病、高脂血症、慢性肾功能不全、既往痛风病史,以及入院前12个月内最近一次血尿酸水平。 3. 急性胰腺炎相关临床特征 包括是否为首次急性胰腺炎发作、疾病严重程度分级、病因分型、是否合并器官衰竭(包括肾功能衰竭及呼吸功能衰竭)。 4. 住院期间临床管理指标 包括住院天数、住院费用、入院后24小时内液体复苏量、利尿剂使用情况、抗生素使用情况、肠内及/或肠外营养支持,以及是否接受连续肾脏替代治疗(CRRT)或血浆置换等特殊治疗。 5. 痛风相关治疗情况 包括降尿酸药物使用、预防复发药物使用、糖皮质激素、非甾体抗炎药(NSAIDs)及秋水仙碱使用情况。 6. 实验室检查指标 包括血尿酸(UA)、尿素氮(BUN)、血肌酐(Cr)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、空腹血糖(FBG)及C反应蛋白(CRP)。 二、数据采集与管理 本研究所有数据均来源于医院电子病历系统及既往健康档案,由研究者使用标准化数据采集表进行信息提取与整理。数据录入采用Microsoft Excel进行初步整理,统计分析使用SPSS软件(版本18.0)完成。本研究未使用电子数据采集系统(EDC)。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Methods – Data Collection 1. Clinical data collection This retrospective study collected clinical data from the hospital electronic medical record system and patients' previous health records. (1) Baseline characteristics Baseline variables included sex, age, height, weight, body mass index (BMI), smoking history, and alcohol consumption history. (2) Medical history and comorbidities Comorbidities included hypertension, coronary artery disease, diabetes mellitus, hyperlipidemia, and chronic renal insufficiency. Gout-related history included previous diagnosis of gout and the most recent serum uric acid level within 12 months prior to admission. (3) Clinical characteristics of acute pancreatitis Variables related to acute pancreatitis included first episode of acute pancreatitis, disease severity classification, etiology, and presence of organ failure, including renal failure and respiratory failure. (4) In-hospital management and clinical outcomes In-hospital variables included length of hospital stay, total hospitalization cost, fluid resuscitation volume within the first 24 hours of admission, use of diuretics, antibiotic therapy, enteral and/or parenteral nutritional support, and advanced treatments such as continuous renal replacement therapy (CRRT) or plasma exchange. (5) Gout-related treatments Gout-related medications included urate-lowering therapy, prophylactic anti-gout medications, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and colchicine. (6) Laboratory measurements Laboratory parameters included serum uric acid (UA), blood urea nitrogen (BUN), serum creatinine (Cr), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), and C-reactive protein (CRP). 2. Data management and statistical software All data were extracted and recorded using a standardized data collection form. Initial data entry and cleaning were performed using Microsoft Excel. Statistical analyses were conducted using SPSS (version 18.0). No electronic data capture (EDC) system was used in this study.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-05-27 08:45:30